EPS for Aerie Pharmaceuticals, Inc. (AERI) Expected At $-1.47

February 25, 2018 - By Marie Mckinney

 EPS for Aerie Pharmaceuticals, Inc. (AERI) Expected At $ 1.47
Investors sentiment increased to 1.73 in 2017 Q3. Its up 0.56, from 1.17 in 2017Q2. It increased, as 14 investors sold Aerie Pharmaceuticals, Inc. shares while 41 reduced holdings. 26 funds opened positions while 69 raised stakes. 34.42 million shares or 8.89% more from 31.61 million shares in 2017Q2 were reported.
Point72 Asia (Hong Kong) Limited holds 0.01% or 230 shares in its portfolio. Sabby Mgmt Ltd Liability Corporation invested in 4,726 shares or 0.02% of the stock. Prudential Fin stated it has 56,520 shares. Invesco Ltd owns 407,068 shares. Schwab Charles Inv Mngmt Inc reported 152,668 shares. Tower Ltd Company (Trc) reported 0.02% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Moreover, Legal And General Grp Inc Public Ltd Co has 0% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Raymond James invested in 0.01% or 58,633 shares. Ahl Prns Ltd Liability Partnership reported 6,932 shares. Alliancebernstein Limited Partnership has invested 0.02% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Voya Investment Mngmt Lc invested 0.05% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Weiss Multi has 50,000 shares. Castleark Ltd Liability Corporation has 132,118 shares for 0.2% of their portfolio. Barclays Plc stated it has 5,710 shares or 0% of all its holdings. Tudor Corp Et Al holds 11,010 shares.

Analysts expect Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) to report $-1.47 EPS on March, 6.They anticipate $0.60 EPS change or 68.97 % from last quarter’s $-0.87 EPS. After having $-0.89 EPS previously, Aerie Pharmaceuticals, Inc.’s analysts see 65.17 % EPS growth. The stock increased 2.47% or $1.3 during the last trading session, reaching $53.85. About 206,593 shares traded. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has risen 180.20% since February 25, 2017 and is uptrending. It has outperformed by 163.50% the S&P500.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

Among 15 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 15 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aerie Pharmaceuticals had 47 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Buy” rating by Canaccord Genuity given on Tuesday, December 20. The firm has “Buy” rating by Aegis Capital given on Tuesday, November 1. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has “Buy” rating given on Tuesday, September 20 by H.C. Wainwright. The company was reinitiated on Friday, February 16 by H.C. Wainwright. The rating was maintained by Cantor Fitzgerald on Thursday, September 15 with “Buy”. The firm has “Buy” rating by Cantor Fitzgerald given on Friday, June 3. The firm has “Market Outperform” rating by JMP Securities given on Wednesday, September 9. Canaccord Genuity maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) on Wednesday, January 24 with “Buy” rating. The rating was maintained by Stifel Nicolaus with “Buy” on Thursday, September 15. Canaccord Genuity maintained the shares of AERI in report on Monday, October 16 with “Buy” rating.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. The company has market cap of $2.11 billion. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It currently has negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

More notable recent Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) news were published by: Businesswire.com which released: “Aerie Pharmaceuticals Announces Appointment of Scott Cassady as Regional Sales …” on February 12, 2018, also Nasdaq.com with their article: “Aerie Pharmaceuticals Breaks Below 200-Day Moving Average – Notable for AERI” published on January 31, 2018, Businesswire.com published: “Aerie Pharmaceuticals Announces Appointment of John LaRocca as General Counsel” on February 20, 2018. More interesting news about Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) were released by: Businesswire.com and their article: “Aerie Pharmaceuticals Announces Appointment of Brad Fuller as Director of …” published on February 08, 2018 as well as Businesswire.com‘s news article titled: “Aerie Pharmaceuticals Announces Appointment of Tad Heitmann as Head of …” with publication date: February 01, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: